|
All treated patients (N = 20)
|
|---|
|
Treatment-emergent adverse events
|
Frequency (%)
|
|---|
|
Gastroenteritis
|
5 (25%)
|
|
Vomiting
|
2 (10%)
|
|
Upper respiratory tract infection
|
2 (10%)
|
|
Mouth ulceration
|
1 (5%)
|
|
Paraesthesia oral
|
1 (5%)
|
|
Diarrhea
|
1 (5%)
|
|
Application site dryness
|
1 (5%)
|
|
Application site rash
|
1 (5%)
|
|
Influenza
|
1 (5%)
|
|
Viral infection
|
1 (5%)
|
|
Viral upper respiratory tract infection
|
1 (5%)
|
|
Otitis media
|
1 (5%)
|
|
Tonsillitis
|
1 (5%)
|
|
Limb injury
|
1 (5%)
|
|
Eosinophil count abnormal
|
1 (5%)
|
|
Neck pain
|
1 (5%)
|
|
Pain in extremity
|
1 (5%)
|
|
Dizziness
|
1 (5%)
|
|
Lethargy
|
1 (5%)
|
|
Psychomotor hyperactivity
|
1 (5%)
|
|
Enuresis
|
1 (5%)
|
|
Stereotypy
|
1 (5%)
|
|
Nightmare
|
1 (5%)
|
|
Pruritus
|
1 (5%)
|
|
Eczema
|
1 (5%)
|
|
Rash pruritic
|
1 (5%)
|
- Note. Frequency reflects all reported events; individual patients may have experienced more than one AE
